Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Modified Renshen Yangrong is a Traditional Chinese Medicine (TCM) decoction developed by the Affiliated Hospital of Hubei University of Traditional Chinese Medicine (Hubei Provincial Hospital of TCM). It is a specialized modification of the classic Song Dynasty formula *Renshen Yangrong Tang* (Ginseng Nutritive Decoction). The formula is primarily indicated for Qi deficiency syndrome, characterized by symptoms such as chronic fatigue, shortness of breath, and general physical depletion. In modern clinical practice at the developing institution, it is frequently utilized to manage cancer-related fatigue (CRF) and to support recovery in patients undergoing chemotherapy or surgery. The modification typically involves adjusting the ratios or adding specific herbs to the core components—which include *Panax ginseng*, *Astragalus membranaceus*, and *Angelica sinensis*—to enhance its tonifying effects on the Spleen and Heart and its ability to nourish both Qi and Blood. Research conducted at the Hubei institution suggests that the formula may help regulate immune function, specifically by modulating T-lymphocyte subsets and improving hemoglobin levels in debilitated patients.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on modified renshen yangrong.